(Q41321498)

29 September 2017

1 reference

title

Treatment regimens for patients with toxoplasmic encephalitis (English)

1 reference

29 September 2017

Fung HB

1

1 reference

29 September 2017

Kirschenbaum HL

series ordinal

2

1 reference

29 September 2017

language of work or name

1 reference

1 November 1996

1 reference

29 September 2017

published in

Clinical Therapeutics

1 reference

29 September 2017

volume

18

1 reference

29 September 2017

issue

6

1 reference

29 September 2017

page(s)

1037-56; discussion 1036

1 reference

Opportunistic/nosocomial infections. Treatment and developmental therapeutics. Toxoplasmosis

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Role of gamma interferon in Toxoplasma gondii infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Toxoplasmosis: the time has come

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Prevention, diagnosis, and treatment of fetal toxoplasmosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

An overview of the problem of toxoplasmosis and pneumocystosis in AIDS in the USA: implication for future therapeutic trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Toxoplasmosis in AIDS: keeping the lid on

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Therapeutic approaches for AIDS-related toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Comparison of two medications in central nervous system toxoplasmosis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

NIH conference. Recent advances in the management of AIDS-related opportunistic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

A retrospective study of primary and maintenance therapy of toxoplasmic encephalitis with oral clindamycin and pyrimethamine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Treatment of acute toxoplasmosis with oral clindamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Role of clindamycin in the treatment of acute toxoplasmosis of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Toxoplasmosis of the central nervous system in the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Azithromycin for cerebral toxoplasmosis in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Efficacy of atovaquone in treatment of toxoplasmosis in patients with AIDS. The NIAID-Clinical Center Intramural AIDS Program

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

5-Fluoro-uracil-clindamycin for treatment of cerebral toxoplasmosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Cotrimoxazole therapy of Toxoplasma gondii encephalitis in AIDS patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Salvage trial of trimetrexate-leucovorin for the treatment of cerebral toxoplasmosis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Activity of clarithromycin alone or in combination with other drugs for treatment of murine toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Effectiveness of spiramycin for treatment of congenital Toxoplasma gondii infection in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

1 reference

7 January 2021

Activity of minocycline against Toxoplasma gondii infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Rifabutin is active in murine models of toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Activity of pentamidine and pentamidine analogs against Toxoplasma gondii in cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Treatment of acute experimental toxoplasmosis with investigational poloxamers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Interferon-gamma: the major mediator of resistance against Toxoplasma gondii

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Low-dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Cerebral toxoplasmosis and co-trimoxazole prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. The PRIO Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Effect of prophylaxis against Pneumocystis carinii on toxoplasma encephalitis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

Prophylaxis for opportunistic infections in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

New perspectives in the chemoprophylaxis of toxoplasmosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2896%2980059-2

7 January 2021

10.1016/S0149-2918(96)80059-2

Identifiers

DOI

1 reference

29 September 2017

1 reference